Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No, it doesn’t. They simply decided not to register with the SEC and become obligated to file their disclosures in Edgar.
The RS will happen. They gave their insiders a bunch of preferred stock that is unaffected by the RS. After the RS happens, all those preferred will be converted and dumped.
this says it was >Strategic Asset Leasing, Inc. a/k/a Anew Medical, Inc/“Company”) respectfully requests that the Securities and Exchange Commission (the “Commission”) consent to the withdrawal of the Company’s registration statement on Form 10 together with all exhibits and amendments thereto (collectively, the “Registration Statement”), filed with the Commission on July 11, 2022.
No, the reverse split wasn’t cancelled.
reverse split canceled> https://www.otcmarkets.com/filing/html?id=16073389&guid=x9P-k6tgVvUTOth
wow> Peter Moriarty has extensive experience in the pharmaceutical industry both in the United States and internationally. He was a co-founder of Shire Pharmaceuticals, an international specialty pharmaceutical company acquired by Takeda Pharmaceuticals (TAK: NASDAQ). Until its acquisition, Peter was the Executive Chairman of Prismic Pharmaceuticals, a specialty pharmaceutical company he co-founded in 2011, and where he was also the CEO from 2013 to 2018. Prismic was acquired by FSD Pharma (HUGE: NASDAQ). Peter’s earlier career spanned management positions within Warner-Lambert/ Parke-Davis and Schering- Plough, including leadership positions overseas as well as in the United States. Additionally, he led the Sales Force Automation and Software Products Division at Walsh America (acquired by NDC), and led Corporate Development at Ixsys /Applied Molecular Evolution acquired by Eli Lilly (LLY – NYSE). He was subsequently the founder, Chairman and Chief Executive Officer of iPhysicianNet, Inc. and Clinical Information Network.
https://www.anewmeds.com/ Strategic Asset Leasing is becoming: Anew Medical, Inc., We are committed to the development of disease-modifying therapies for age-related cognitive and neurodegenerative disorders and cancer.
What happens with every RS on the OTC?
This one will have an O/S of just over 400K shares, and the preferred B conversions will become over 40M shares ready to dump...
Handwriting's pretty much on the wall...
So what do you think the stock will start going down right?
The RS is still pending, 2500-1. Then they'll start converting those 405,250 Preferred B shares at 100 common shares each (40,525,000 shares) into the resulting $2.50 PPS. Straight math would show the "acquisition" value they gave themselves is $100M for a company with zero revenue, but when they begin to dump that stock, the PPS will inevitably tank. Still a great deal for those who got that stock essentially free, already off restriction since they've held it over a year.
My post applies here as well
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170508111
Per Today's Quarterly Report Ending 9/30/22:
On September 12, 2022, the Company acquired five market-approved anti-cancer drugs approved for sale in Germany for $1,386,766. The purchase
price consisted of cash for $39,248 and a short-term promissory note for $1,347,518. The purchase price represents the fair value of the intangible asset
based on the net present value of the projected gross profit to be generated by the licenses. The licenses are not in use and will be amortized over the
useful life.
The total licenses were $2,123,750 and 736,983 at September 30, 2022 and December 31, 2021, respectively, in the accompanying consolidated balance
sheet.
Patents
The Company is filing for an Alzheimer and an ALS patent. As of September 30, 2022, the patents have not been finalized. Once the patents are
declared effective, the Patents will be amortized over the shorter of a patent's useful life and its legal useful life. The cost incurred as of September
30, 2022 was $36,400 and reported as patents in the accompanying consolidated balance sheet.
TONY NEWTON, Miller attorney
Dont worry bout Newton. We got him Emails
He wasn't new at that time. Goes all the way back ta 2017 with Miller.
GRAND JURY ruled on this Miller sht. Do ya know the material they ruled upon?
And here is the letter from the new attorney, Anthony Newton, using that newly created history from 2015 - 2019 to argue that LEAS isn't nor has it ever been a shell company:
https://backend.otcmarkets.com/otcapi/company/financial-report/252280/content
You can't just hide old filings by making them inactive then invent a new history to meet your agenda of wanting to create free trading stock for Bolbat and Mark Miller to dump into the market.
Shame on this attorney Anthony Newton for facilitating this scam. Tick Tock until he gets banned too like Saha and Paradiso and then these new filings are made inactive too.
From the presentation today.....
pending reverse split 2500 to 1.
2.75 million private equity raised.
I am out, better places to put my money.
GLTA.
The doc can't create any enthusiasm amongst the investors at this point. Investors summit today and not a peep.
+50% close. 900dollar in buys end of day. And 2600 dollar slap earlier. Anew Medical. Q3 closed 9/30. Should see filing soon. Why the yield sign?
License Agreement?
Feel like something happening behind scene.
nice ,i have mine. one of these day LEAS :o)
True. Should have said farther..
Already got decimated when the RS was announced months back
My bet it’s been placed
Now everyone is in the same page. Either finra approves the RS and we get decimated, or the “good” dr gives up and cancels it. Place your bets.
So this mean the RS it’s been cancelled?
Waiting for updated documents from the company. Form 10 being canceled usually means changes coming. R/S is already built into the price, if it happens.
That didn’t cancel the RS.
Form 10 filing has been canceled. Until we get further info from the company it is all speculation.
https://www.otcmarkets.com/filing/html?id=16073389&guid=e7R-k6fu0Rd-B3h
Now the issue is the FNRA will approve it or not?
It is neither approved nor disapproved. If you read through that whole document, you'll see the alleged owners of ANEW gave themselves a bunch of preferred stock for their "ownership" that would not be affected by the RS. That means that current shareholders get wiped, and the new shareholders have a nice PPS to dump into.
Read the document right it’s been submitted to FNRA
Also on November 1, 2021, the shareholders of Strategic Asset Leasing, Inc., approved a name change and approved a 1-for-2500 reverse split. On April 19, 2022, the Company filed an Articles of Amendment with the State of Wyoming, changing its name to “ANEW MEDICAL, INC..” and requested the contemplated 1-for- 2,500 reverse split. During January 2022 and in accordance with SEC Rule 10b-17 and FINRA Rule 6490, the Company submitted documents and other information to FINRA in furtherance of pursuing and obtaining approval of the subject reverse stock split and name change. The Company must submit additional documents requested by, and necessary to obtain approval of, FINRA in connection with the subject reverse stock split and name change. As of August 15, 2022, the reverse split and name change have not been declared effective.
But still FNRA did not approve it yet
So it’s not approved
Also on November 1, 2021, the shareholders of Strategic Asset Leasing, Inc., approved a name change and approved a 1-for-2500 reverse split. On April 19, 2022, the Company filed an Articles of Amendment with the State of Wyoming, changing its name to “ANEW MEDICAL, INC..” and requested the contemplated 1-for- 2,500 reverse split. During January 2022 and in accordance with SEC Rule 10b-17 and FINRA Rule 6490, the Company submitted documents and other information to FINRA in furtherance of pursuing and obtaining approval of the subject reverse stock split and name change. The Company must submit additional documents requested by, and necessary to obtain approval of, FINRA in connection with the subject reverse stock split and name change. As of August 15, 2022, the reverse split and name change have not been declared effective.
Yes. Check out the quarterly disclosure issued in August, page 10:
https://www.otcmarkets.com/otcapi/company/financial-report/343416/content
$LEAS ~I don't know what's happening behind the scenes, but watching the trading and how the market makers are keeping it down as low as they can keep it appears to me that someone is loading up the cheapies for what's to come! Looking forward to some updates on everything happening and how that equates to a much higher market cap here soon!
How many times are you going to ask the same question
Do you think the RS will happen??
No. The only thing cancelled/withdrawn was their registration statement with the SEC. Their latest financials shows the award of a bunch of convertible preferred stock and mentions specifically it would not be impacted by a RS.
Convertible preferred that isn't subject to a RS, wonder what they're planning?
Is it for sure the R/S been canceled?
$LEAS ~Very nice that the RS has been cancelled in July! People can shut up about it for good! ~People can load all of the available cheapies without any fear now!
Also the filing that includes the reverse split has been canceled. Some changes coming. Traders hear R/S and sell. Some are going to be very surprised when the announced R/S is canceled.
Notice the filing below cancels all exhibits and amendments, including the mentioned R/S.
consent to the withdrawal of the Company’s registration statement on Form 10 together with all exhibits and amendments thereto (collectively, the “Registration Statement”), filed with the Commission on July 11, 2022.
Did FNRA approve the RS?
Followers
|
903
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
155603
|
Created
|
10/19/07
|
Type
|
Free
|
Moderators |
Medical product development and commercialization. The Company recently acquired five generic oncology drugs approved and manufactured in Germany and they plan to gain approval for these drugs in the US in 2023. The Company is preparing for a pivotal Phase 3 study of an anti-cancer antibody product that is highly similar to Genentech/Roche's brand name Avastin (bevacizumab), the Company has licensed a needle-free jet injector for drug delivery, and the Company is in the pre-clinical stages of development of a gene therapy product candidate based on the delivery of a human alpha-Klotho gene and protein to prevent and/or treat neurodegenerative diseases such as Alzheimer's and Lou Gehrig's disease (ALS). Other product candidates will stem from these platform technologies of pharmaceuticals, biologics, and gene therapy.
The Company's medical R&D facilities are in the U.S. (near the University of Nebraska Medical Center, Omaha, Nebraska) and in Barcelona, Spain (Autonomous Universitat de Barcelona). Each R&D facility is comprised of over 4,000 sq ft of R&D and office space, currently leased and equipped with research equipment, incubators, tissue culture facilities for production of plasmid DNA, HEPA-filtered hoods for aseptic handling, and testing equipment (PCR, spectrophotometers, microscopes, etc). The generic oncology drugs are manufactured in Germany. With future funding, the Company plans to acquire or build a GMP manufacturing facility to supply novel plasmid DNA ("transgenes") to be used in gene therapy programs, to provide contract manufacturing revenue, and for commercial product manufacturing.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |